Effective as of December 31, 2020, Yi Ching Yau, the Company’s current Chief Accounting Officer, resigned from her role as principal accounting officer. Ms. Yau will continue in her role as Chief Accounting Officer. Effective January 1, 2021, the Board of Directors of BridgeBio Pharma, Inc. (the “Company”) designated Brian C. Stephenson, Ph.D., CFA, the Company’s current Chief Financial Officer and principal financial officer, as its principal accounting officer, as such term is used for purposes of the rules and regulations of the Securities and Exchange Commission. Dr. Stephenson will oversee the Company’s accounting matters. Dr. Stephenson has served in his current role as the Company’s Chief Financial Officer and principal financial officer since October 2018. Prior to joining the Company, Dr. Stephenson served as Partner and the Head of Life Sciences for Capital IP Investment Partners, a special situation investment fund, from 2015 to 2018.